Reiter-Owona I, Hlobil H, Enders M, Klarmann-Schulz U, Gruetzmacher B, Rilling V
Eur J Med Res. 2020; 25(1):59.
PMID: 33228795
PMC: 7686675.
DOI: 10.1186/s40001-020-00458-7.
Dunay I, Gajurel K, Dhakal R, Liesenfeld O, Montoya J
Clin Microbiol Rev. 2018; 31(4).
PMID: 30209035
PMC: 6148195.
DOI: 10.1128/CMR.00057-17.
Mageed S, Cunningham F, Hung A, Silvestre H, Wen S, Blundell T
Antimicrob Agents Chemother. 2014; 58(11):6345-53.
PMID: 25049241
PMC: 4249369.
DOI: 10.1128/AAC.02640-14.
CHODOS J, HABEGGER-CHODOS H
Can Med Assoc J. 1963; 88:505-11.
PMID: 14020958
PMC: 1921073.
Gubbels M, Li C, Striepen B
Antimicrob Agents Chemother. 2002; 47(1):309-16.
PMID: 12499207
PMC: 149035.
DOI: 10.1128/AAC.47.1.309-316.2003.
Laboratory-acquired parasitic infections from accidental exposures.
Herwaldt B
Clin Microbiol Rev. 2001; 14(4):659-88, table of contents.
PMID: 11585780
PMC: 88999.
DOI: 10.1128/CMR.14.3.659-688.2001.
Human platelet inhibition of Toxoplasma gondii growth.
Chumpitazi B, Simon J, Polack B, Peyron F, Picot S, Ricard J
Clin Exp Immunol. 1998; 111(2):325-33.
PMID: 9486399
PMC: 1904904.
DOI: 10.1046/j.1365-2249.1998.00499.x.
Kinetics study and characterisation of target excreted/secreted antigens of immunoglobulin G, M, A and E antibodies from mice infected with different strains of Toxoplasma gondii.
Cazabonne P, Bessieres M, Seguela J
Parasitol Res. 1994; 80(1):58-63.
PMID: 8153127
DOI: 10.1007/BF00932625.
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Chang H, Arsenijevic D, Comte R, Polak A, Then R, Pechere J
Antimicrob Agents Chemother. 1994; 38(8):1803-7.
PMID: 7986011
PMC: 284639.
DOI: 10.1128/AAC.38.8.1803.
[An ophthalmologic contribution to the problem of congenital toxoplasmosis in siblings].
Rieger H
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1965; 168(5):438-54.
PMID: 5296334
DOI: 10.1007/BF02464811.
Toxoplasma and toxoplasmosis.
Koul R
Indian J Pediatr. 1973; 40(306):261-6.
PMID: 4770908
DOI: 10.1007/BF02817866.
Toxoplasmosis in the adult.
Remington J
Bull N Y Acad Med. 1974; 50(2):211-27.
PMID: 4592097
PMC: 1749356.
Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease.
Alford Jr C, Stagno S, Reynolds D
Bull N Y Acad Med. 1974; 50(2):160-81.
PMID: 4592095
PMC: 1749345.
Current status of toxoplasma and toxoplasmosis: a review.
Quinn P, McCraw B
Can Vet J. 1972; 13(11):247-62.
PMID: 4567530
PMC: 1695956.
[The possibility of transmission of toxoplasma by means of blood transfusions].
Janitschke K, Werner H, Hasse W
Blut. 1974; 29(6):407-15.
PMID: 4451734
DOI: 10.1007/BF01633676.
[Toxoplasmosis as a probable mutagenic factor].
Rieger H
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1966; 170(3):223-34.
PMID: 4231159
DOI: 10.1007/BF02429458.
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.
Chang H, Pechere J
Antimicrob Agents Chemother. 1988; 32(4):524-9.
PMID: 2837140
PMC: 172214.
DOI: 10.1128/AAC.32.4.524.
In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii.
Chang H, Jefford C, Pechere J
Antimicrob Agents Chemother. 1989; 33(10):1748-52.
PMID: 2589842
PMC: 172749.
DOI: 10.1128/AAC.33.10.1748.
In vitro and in vivo effects of doxycycline on Toxoplasma gondii.
Chang H, Comte R, Pechere J
Antimicrob Agents Chemother. 1990; 34(5):775-80.
PMID: 2360817
PMC: 171690.
DOI: 10.1128/AAC.34.5.775.
Therapy and prophylaxis of systemic protozoan infections.
Van Voorhis W
Drugs. 1990; 40(2):176-202.
PMID: 2121456
DOI: 10.2165/00003495-199040020-00002.
